KR20050062663A - 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체 및자손 전달 가능한 상기 인간 인공 염색체를 포함하는비인간 동물 - Google Patents
인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체 및자손 전달 가능한 상기 인간 인공 염색체를 포함하는비인간 동물 Download PDFInfo
- Publication number
- KR20050062663A KR20050062663A KR1020057009130A KR20057009130A KR20050062663A KR 20050062663 A KR20050062663 A KR 20050062663A KR 1020057009130 A KR1020057009130 A KR 1020057009130A KR 20057009130 A KR20057009130 A KR 20057009130A KR 20050062663 A KR20050062663 A KR 20050062663A
- Authority
- KR
- South Korea
- Prior art keywords
- human
- mouse
- chromosome
- human antibody
- antibody
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 105
- 210000003917 human chromosome Anatomy 0.000 title abstract description 96
- 210000000349 chromosome Anatomy 0.000 claims abstract description 111
- 239000012634 fragment Substances 0.000 claims abstract description 90
- 238000000034 method Methods 0.000 claims abstract description 44
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 126
- 210000004027 cell Anatomy 0.000 claims description 103
- 241000699670 Mus sp. Species 0.000 claims description 53
- 230000000717 retained effect Effects 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 210000004408 hybridoma Anatomy 0.000 claims description 15
- 230000003053 immunization Effects 0.000 claims description 14
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 12
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 12
- 210000004988 splenocyte Anatomy 0.000 claims description 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 210000005253 yeast cell Anatomy 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 7
- 108700028369 Alleles Proteins 0.000 claims description 6
- 241000238631 Hexapoda Species 0.000 claims description 6
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 6
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 6
- 210000004102 animal cell Anatomy 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 108700019146 Transgenes Proteins 0.000 claims description 4
- 238000002823 phage display Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 210000000688 human artificial chromosome Anatomy 0.000 abstract description 62
- 241001465754 Metazoa Species 0.000 abstract description 29
- 210000004994 reproductive system Anatomy 0.000 abstract 1
- 239000013598 vector Substances 0.000 description 55
- 230000002759 chromosomal effect Effects 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 30
- 239000012980 RPMI-1640 medium Substances 0.000 description 21
- 239000002609 medium Substances 0.000 description 20
- 230000005945 translocation Effects 0.000 description 19
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 18
- 238000012546 transfer Methods 0.000 description 17
- 230000008685 targeting Effects 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 14
- 108091008146 restriction endonucleases Proteins 0.000 description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 210000003411 telomere Anatomy 0.000 description 13
- 108091035539 telomere Proteins 0.000 description 13
- 102000055501 telomere Human genes 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 210000002230 centromere Anatomy 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 9
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 9
- 229940097277 hygromycin b Drugs 0.000 description 9
- 241000287828 Gallus gallus Species 0.000 description 8
- 210000004507 artificial chromosome Anatomy 0.000 description 8
- 235000013330 chicken meat Nutrition 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 230000021121 meiosis Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 102100037392 Phosphoglycerate kinase 2 Human genes 0.000 description 7
- 108010006785 Taq Polymerase Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 7
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 7
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 7
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 7
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 210000004602 germ cell Anatomy 0.000 description 7
- 108010008054 testis specific phosphoglycerate kinase Proteins 0.000 description 7
- 102100030500 Heparin cofactor 2 Human genes 0.000 description 6
- 101001082432 Homo sapiens Heparin cofactor 2 Proteins 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000009261 transgenic effect Effects 0.000 description 6
- 101100384866 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COT1 gene Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 210000004754 hybrid cell Anatomy 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000011813 knockout mouse model Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 4
- 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 4
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000037308 hair color Effects 0.000 description 4
- 101150113423 hisD gene Proteins 0.000 description 4
- 101150079312 pgk1 gene Proteins 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000010473 stable expression Effects 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010004020 Immunoglobulin lambda-Chains Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 3
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
- QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101100302211 Arabidopsis thaliana RNR2A gene Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014392 Cat-eye syndrome Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- 241001635598 Enicostema Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102100029572 Immunoglobulin kappa constant Human genes 0.000 description 1
- 108010090227 Immunoglobulin kappa-Chains Proteins 0.000 description 1
- 102100029620 Immunoglobulin lambda constant 2 Human genes 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101150002896 RNR2 gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (15)
- (a) 재배열되어 있지 않은 인간 항체 중쇄 유전자좌, (b) 재배열되어 있지 않은 인간 항체 κ 경쇄 유전자좌 및 (c) 재배열되어 있지 않은 인간 항체 λ 경쇄 유전자좌 중 하나 이상이 인간 유래 염색체 단편 상에 보유되어 있고, 상기 (a), (b) 및 (c) 중 하나 이상이 마우스 염색체에 삽입되어 있으며, 또한 적어도 내인성 중쇄의 양쪽 대립유전자 및 내인성 κ 경쇄의 양쪽 대립유전자가 불활성화되어 있고, 상기 마우스의 혈청 중에 인간 항체 중쇄, 인간 항체 κ 경쇄 및 인간 항체 λ 경쇄를 발현하는, (a), (b) 및 (c)를 보유하는 인간 항체 생산 마우스.
- 제1항에 있어서, 인간 유래 염색체 단편 상에 보유된 재배열되어 있지 않은 인간 항체 중쇄 유전자좌, 마우스 염색체에 삽입된 재배열되어 있지 않은 인간 항체 κ 경쇄 유전자좌, 및 인간 유래 염색체 단편 상에 보유된 인간 항체 λ 경쇄 유전자좌를 보유하는 인간 항체 생산 마우스.
- 제1항에 있어서, 인간 항체 중쇄 유전자좌가 인간 유래 염색체 단편 상에 보유되는 인간 항체 생산 마우스.
- 제3항에 있어서, 인간 항체 중쇄 유전자좌가 ΔHAC 또는 ΔΔHAC 상에 보유되는 인간 항체 생산 마우스.
- 제1항에 있어서, 인간 항체 λ 경쇄 유전자좌가 인간 유래 염색체 단편 상에 보유되는 인간 항체 생산 마우스.
- 제5항에 있어서, 인간 항체 λ 경쇄 유전자좌가 ΔHAC 또는 ΔΔHAC 상에 보유되는 인간 항체 생산 마우스.
- 제1항에 있어서, 인간 항체 κ 경쇄 유전자좌가 마우스 염색체에 삽입된 인간 항체 생산 마우스.
- 제7항에 있어서, 인간 항체 κ 트랜스 유전자(transgene) Kco5가 마우스 염색체에 삽입되어 있는 인간 항체 생산 마우스.
- 제1항에 있어서, 인간 항체 중쇄 유전자좌 및 λ 경쇄 유전자좌가 ΔHAC 또는 ΔΔHAC 상에 보유되고, 인간 항체 κ 트랜스 유전자 Kco5가 마우스 염색체에 삽입되어 있는 인간 항체 생산 마우스.
- 제1항에 있어서, 마우스가 키메라 마우스가 아닌 것을 특징으로 하는 인간 항체 생산 마우스.
- 제1항 내지 제10항 중 어느 한 항에 기재된 마우스를 면역화시키는 단계, 및 상기 마우스로부터 폴리클로날 항체를 얻는 단계를 포함하는, 항체의 제조 방법.
- 제11항에 있어서, 폴리클로날 항체가 마우스의 혈액으로부터 얻어지는 방법.
- 제1항 내지 제10항 중 어느 한 항에 기재된 마우스를 원하는 항원으로 면역화시키는 단계, 계속해서 상기 마우스 유래의 비장 세포를 마우스 골수종 세포와 융합시켜 하이브리도마를 제조하는 단계, 및 상기 항원에 대한 인간 면역글로불린 중쇄와 경쇄를 포함하는 모노클로날 항체를 제조하는 단계를 포함하는, 항체의 제조 방법.
- 제1항 내지 제10항 중 어느 한 항에 기재된 마우스를 원하는 항원으로 면역화시키는 단계, 계속해서 상기 마우스 유래의 비장 세포를 마우스 골수종 세포와 융합시켜 하이브리도마를 제조하는 단계, 이 하이브리도마로부터 인간 항체 유전자의 적어도 가변 영역 부분을 단리하여 상기 인간 항체 유전자를 동물 세포, 효모 세포 또는 곤충 세포에 도입하는 단계, 및 이 세포를 인간 항체 유전자를 발현할 수 있는 조건하에서 배양하여 상기 항원에 대한 인간 면역글로불린 중쇄와 경쇄의 적어도 가변 영역 부분을 포함하는 모노클로날 항체를 제조하는 단계를 포함하는, 항체의 제조 방법.
- 제1항 내지 제10항 중 어느 한 항에 기재된 마우스를 원하는 항원으로 면역화시키는 단계, 상기 마우스의 B 세포에서 유래한 인간 항체 유전자의 적어도 가변 영역 부분을 파지 디스플레이법에 의해 선별하여 선별된 인간 항체 유전자를 동물 세포, 효모 세포 또는 곤충 세포에 도입하는 단계, 및 이 세포를 인간 항체 유전자를 발현할 수 있는 조건하에서 배양하여 상기 항원에 대한 인간 면역글로불린 중쇄와 경쇄의 적어도 가변 영역 부분을 포함하는 모노클로날 항체를 제조하는 단계를 포함하는, 항체의 제조 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPJP-P-2001-00142371 | 2001-05-11 | ||
JP2001142371 | 2001-05-11 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037014594A Division KR100770065B1 (ko) | 2001-05-11 | 2002-05-10 | 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는비인간 동물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050062663A true KR20050062663A (ko) | 2005-06-23 |
KR100583331B1 KR100583331B1 (ko) | 2006-05-26 |
Family
ID=18988681
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037014594A KR100770065B1 (ko) | 2001-05-11 | 2002-05-10 | 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는비인간 동물 |
KR1020057009130A KR100583331B1 (ko) | 2001-05-11 | 2002-05-10 | 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체 및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는 비인간 동물 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037014594A KR100770065B1 (ko) | 2001-05-11 | 2002-05-10 | 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는비인간 동물 |
Country Status (12)
Country | Link |
---|---|
US (6) | US7476536B2 (ko) |
EP (3) | EP1391511B1 (ko) |
JP (2) | JP4115281B2 (ko) |
KR (2) | KR100770065B1 (ko) |
CN (2) | CN1789416B (ko) |
AT (1) | ATE398172T1 (ko) |
AU (2) | AU2002309063B8 (ko) |
CA (2) | CA2446968C (ko) |
DE (1) | DE60227067D1 (ko) |
DK (1) | DK1391511T3 (ko) |
HK (1) | HK1089480A1 (ko) |
WO (1) | WO2002092812A1 (ko) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
US7476536B2 (en) | 2001-05-11 | 2009-01-13 | Kirin Pharma Kabushiki Kaisha | Artificial human chromosome containing human antibody a light chain gene |
US7435871B2 (en) * | 2001-11-30 | 2008-10-14 | Amgen Fremont Inc. | Transgenic animals bearing human Igλ light chain genes |
US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
CA3079874C (en) | 2004-10-22 | 2023-01-03 | Revivicor, Inc. | Ungulates with genetically modified immune systems |
WO2006061723A2 (en) | 2004-12-06 | 2006-06-15 | Kirin Beer Kabushiki Kaisha | Human monoclonal antibodies to influenza m2 protein and methods of making and using same |
TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
JP4895100B2 (ja) * | 2006-05-01 | 2012-03-14 | 国立大学法人鳥取大学 | 内在遺伝子を含まないヒト人工染色体ベクター |
WO2007137114A2 (en) * | 2006-05-17 | 2007-11-29 | Pioneer Hi-Bred International, Inc. | Artificial plant minichromosomes |
CN101522717A (zh) | 2006-08-04 | 2009-09-02 | 阿斯利康(瑞典)有限公司 | 针对ErbB2的人抗体 |
EA021255B1 (ru) | 2006-08-28 | 2015-05-29 | Киова Хакко Кирин Ко., Лимитед | Антагонистические моноклональные антитела человека, специфичные в отношении light человека |
ES2625798T3 (es) | 2006-10-02 | 2017-07-20 | E. R. Squibb & Sons, L.L.C. | Anticuerpos humanos que se unen a CXCR4 y usos de los mismos |
CN101626782B (zh) | 2006-12-01 | 2013-03-27 | 梅达雷克斯公司 | 结合cd22的人抗体及其用途 |
CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
AU2007333098A1 (en) | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind CD70 and uses thereof |
EP2185692A4 (en) | 2007-08-10 | 2012-05-02 | Medarex Inc | HCO32 AND HCO27 AND RELATED EXAMPLES |
US8865875B2 (en) | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
WO2009039310A2 (en) | 2007-09-18 | 2009-03-26 | La Jolla Institute For Allergy And Immunology | Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment |
WO2009063722A1 (ja) * | 2007-11-14 | 2009-05-22 | National University Corporation Tottori University | ヒトチトクロームp450遺伝子(クラスター)を含む哺乳動物人工染色体ベクター及びそれを保持する非ヒト哺乳動物 |
WO2009151605A1 (en) * | 2008-06-11 | 2009-12-17 | Jn Biosciences Llc | Expression vectors |
CN106039307A (zh) | 2008-08-05 | 2016-10-26 | 东丽株式会社 | 用于治疗和预防癌症的药物组合物 |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
JP5808249B2 (ja) | 2008-10-20 | 2015-11-10 | アッヴィ・インコーポレイテッド | プロテインaアフィニティークロマトグラフィーを用いる抗体の単離および精製 |
WO2010051288A1 (en) | 2008-10-27 | 2010-05-06 | Revivicor, Inc. | Immunocompromised ungulates |
EA028336B1 (ru) | 2009-03-05 | 2017-11-30 | МЕДАРЕКС Л.Л.Си. | Полностью человеческие антитела, специфические в отношении cadm1 |
ES2571235T3 (es) | 2009-04-10 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3 |
CA2759538C (en) | 2009-04-20 | 2018-07-24 | Oxford Biotherapeutics Ltd | Antibodies specific to cadherin-17 |
EP2949673A1 (en) | 2009-04-27 | 2015-12-02 | Kyowa Hakko Kirin Co., Ltd. | Anti-il-3ra antibody for use in treatment of blood tumor |
US20120231004A1 (en) | 2009-10-13 | 2012-09-13 | Oxford Biotherapeutic Ltd. | Antibodies |
AU2010310748C1 (en) | 2009-10-20 | 2015-11-26 | Abbvie Inc. | Isolation and purification of anti-IL-13 antibodies using Protein A affinity chromatography |
US20110098862A1 (en) | 2009-10-27 | 2011-04-28 | ExxonMobil Research Engineering Company Law Department | Multi-stage processes and control thereof |
JP5796846B2 (ja) | 2009-11-17 | 2015-10-21 | エスエービー エルエルシー | ヒト人工染色体ベクター |
KR101485840B1 (ko) * | 2010-01-06 | 2015-01-23 | 도쿠리츠 다이가쿠 호우진 돗토리 다이가쿠 | 마우스 인공염색체 벡터 |
KR101805520B1 (ko) | 2010-02-04 | 2017-12-07 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
WO2011096528A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
DK2532366T3 (da) | 2010-02-04 | 2017-01-02 | Toray Industries | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer |
RU2598258C2 (ru) | 2010-02-04 | 2016-09-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
PL2532680T3 (pl) | 2010-02-04 | 2015-10-30 | Toray Industries | Kompozycja medyczna do leczenia raka i/lub zapobiegania |
IL300712A (en) * | 2010-06-22 | 2023-04-01 | Regeneron Pharma | Mice with light chain to human |
US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
KR20130097156A (ko) | 2010-07-26 | 2013-09-02 | 트리아니, 인코포레이티드 | 트랜스제닉 동물 및 이의 사용 방법 |
US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
DK2601298T3 (en) | 2010-08-02 | 2017-02-27 | Regeneron Pharma | Mice generating binding proteins comprising VL domains |
RU2608499C2 (ru) | 2010-09-20 | 2017-01-18 | Эббви Инк. | Очистка антител с помощью хроматографии с псевдодвижущимся слоем |
PL2550363T3 (pl) | 2011-02-25 | 2015-05-29 | Regeneron Pharma | Myszy adam6 |
WO2012125735A1 (en) | 2011-03-15 | 2012-09-20 | Abott Laboratories | An integrated approach to the isolation and purification of antibodies |
AR086543A1 (es) | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica |
PT2726508T (pt) | 2011-06-28 | 2017-09-26 | Oxford Biotherapeutics Ltd | Anticorpos para adp-ribosil ciclase 2 |
JP6065592B2 (ja) | 2011-08-04 | 2017-01-25 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
US9181348B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
RU2610428C2 (ru) | 2011-08-04 | 2017-02-10 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
RS61946B1 (sr) | 2011-08-05 | 2021-07-30 | Regeneron Pharma | Humanizovani miševi univerzalnog lakog lakca |
EP3216871B1 (en) | 2011-10-17 | 2021-12-22 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
PT2793567T (pt) | 2011-12-20 | 2019-05-27 | Regeneron Pharma | Murganhos de cadeia leve humanizada |
PT2824114T (pt) | 2012-02-21 | 2019-08-05 | Toray Industries | Composição farmacêutica para o tratamento do cancro |
WO2013125636A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
AU2013223137B2 (en) | 2012-02-21 | 2017-10-19 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
IN2014KN01715A (ko) | 2012-02-21 | 2015-10-23 | Toray Industries | |
MX358224B (es) | 2012-03-30 | 2018-08-10 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado. |
HUE036425T2 (hu) | 2012-03-30 | 2018-07-30 | Toray Industries | Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
WO2013158275A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Cell culture methods to reduce acidic species |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013177118A2 (en) | 2012-05-21 | 2013-11-28 | Abbvie Inc. | Novel purification of non-human antibodies using protein a affinity chromatography |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
EP3597037B1 (en) | 2012-06-12 | 2021-04-28 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
CN104755493B (zh) * | 2012-08-03 | 2020-12-25 | Sab有限责任公司 | 用于在转基因动物中生产人类抗体的复杂的染色体工程 |
DK2840892T3 (en) | 2013-02-20 | 2018-07-23 | Regeneron Pharma | Non-human animals with modified heavy chain immunoglobulin sequences |
BR112015017307A2 (pt) | 2013-03-14 | 2017-11-21 | Abbvie Inc | composições de espécies com baixa acidez e métodos para produção e uso das mesmas |
WO2014142882A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Protein purification using displacement chromatography |
CA2899449A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing the same using displacement chromatography |
WO2014186877A1 (en) | 2013-05-24 | 2014-11-27 | Uger Marni Diane | FasR ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE |
US20160272674A1 (en) | 2013-11-07 | 2016-09-22 | Abbvie Inc. | Isolation and purification of antibodies |
SG10201808083VA (en) | 2014-03-21 | 2018-10-30 | Regeneron Pharma | Vl antigen binding proteins exhibiting distinct binding characteristics |
US10881085B2 (en) | 2014-03-21 | 2021-01-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
ES2726645T3 (es) | 2014-08-01 | 2019-10-08 | Inst Nat Sante Rech Med | Un anticuerpo anti-CD45RC para usar como medicamento |
WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
EP3384030A4 (en) | 2015-12-03 | 2019-07-03 | Trianni, Inc. | IMPROVED IMMUNOGLULINIVITY |
WO2017136734A1 (en) | 2016-02-04 | 2017-08-10 | Trianni, Inc. | Enhanced production of immunoglobulins |
JP6939555B2 (ja) | 2016-03-28 | 2021-09-22 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2019051164A1 (en) | 2017-09-07 | 2019-03-14 | Augusta University Research Institute, Inc. | ANTIBODIES AGAINST PROTEIN 1 OF PROGRAMMED CELL DEATH |
CN109837307B (zh) * | 2017-11-24 | 2023-09-19 | 中国科学院脑科学与智能技术卓越创新中心 | 建立含外源染色体的胚胎干细胞的方法 |
EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
JP6775224B2 (ja) | 2018-03-16 | 2020-10-28 | 国立大学法人鳥取大学 | マウス人工染色体ベクター及びその使用 |
JP2024500747A (ja) | 2020-12-18 | 2024-01-10 | キニクサ ファーマシューティカルズ, リミテッド | タンパク質組成物ならびにそれを産生及び使用するための方法 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2605854A (en) * | 1948-11-18 | 1952-08-05 | Bendix Aviat Corp | Steering mechanism |
US3235953A (en) * | 1961-03-17 | 1966-02-22 | Chrysler Corp | Method of assembling steering gear |
GB1183228A (en) * | 1967-09-12 | 1970-03-04 | Cam Gears Ltd | Improvements in or relating to Steering Gears |
CA1293460C (en) | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5652338A (en) | 1988-03-16 | 1997-07-29 | The United States Of America As Represented By The Department Of Health And Human Services | Neutrophil chemotactic factor |
US5270201A (en) | 1988-03-24 | 1993-12-14 | The General Hospital Corporation | Artificial chromosome vector |
WO1989009219A1 (en) | 1988-03-24 | 1989-10-05 | The General Hospital Corporation | Artificial chromosome vector |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
GB8909218D0 (en) | 1989-04-22 | 1989-06-07 | Medical Res Council | Improvements in or relating to enhancers |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
ATE423195T1 (de) | 1989-07-25 | 2009-03-15 | Cell Genesys Inc | Homologe rekombination für universelle donorzellen und chimerische säugetierzellen |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
AU654284B2 (en) | 1990-06-12 | 1994-11-03 | Baylor College Of Medicine | Method for homologous recombination in animal and plant cells |
US5614396A (en) | 1990-06-14 | 1997-03-25 | Baylor College Of Medicine | Methods for the genetic modification of endogenous genes in animal cells by homologous recombination |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
JPH072125A (ja) * | 1993-04-22 | 1995-01-06 | Toyota Motor Corp | パワーステアリング用トーションバー |
JP2600108Y2 (ja) * | 1993-06-02 | 1999-10-04 | 光洋精工株式会社 | ラックピニオン式油圧パワーステアリング装置 |
US5546319A (en) * | 1994-01-28 | 1996-08-13 | Fujitsu Limited | Method of and system for charged particle beam exposure |
EP0749488A1 (en) | 1994-03-03 | 1996-12-27 | Genentech, Inc. | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders |
DE4411762A1 (de) * | 1994-04-06 | 1995-10-12 | Kolbenschmidt Ag | Gleitlagerwerkstoff |
GB9410446D0 (en) | 1994-05-25 | 1994-07-13 | Cancer Res Campaign Tech | Novel chromosome fragment |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
US5543319A (en) | 1995-03-31 | 1996-08-06 | Fred Hutchinson Cancer Research Center | Recombination-proficient avian/mammalian microcell hybrids |
US6348353B1 (en) * | 1995-06-07 | 2002-02-19 | Case Western Reserve University | Artificial mammalian chromosome |
CN101333516A (zh) | 1995-08-29 | 2008-12-31 | 麒麟医药株式会社 | 嵌合体动物及其制备方法 |
US6632976B1 (en) | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
AU3507297A (en) | 1996-06-26 | 1998-01-14 | Baylor College Of Medicine | Chromosomal rearrangement by insertion of two recombination substrates |
DE69835145T2 (de) * | 1997-02-28 | 2007-06-14 | Kirin Beer K.K. | Transgene Mäuse die ein menschliches Antikörper exprimieren |
AU7057398A (en) | 1997-04-11 | 1998-11-11 | Imperial College Of Science, Technology And Medicine | Chromosome transfer (xmmct) to es cells, induced during the exposure of microcells to radiation |
GB9711167D0 (en) | 1997-05-31 | 1997-07-23 | Babraham The Inst | Telomere-associated chromosome fragmentation |
JP3895437B2 (ja) * | 1997-09-19 | 2007-03-22 | 株式会社ジェイテクト | 動力舵取装置のハウジング構造 |
US6283244B1 (en) * | 1997-10-03 | 2001-09-04 | Visteon Global Technologies, Inc. | Steering mechanism assembly for automotive vehicle |
TWI255853B (en) | 1998-08-21 | 2006-06-01 | Kirin Brewery | Method for modifying chromosomes |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
EP1206906A4 (en) | 1999-08-13 | 2004-12-29 | Kirin Brewery | MOUSE CONTAINING A HUMAN P450 CYTOCHROME |
US6330929B1 (en) * | 1999-10-06 | 2001-12-18 | Trw Inc. | Rack bushing for fluid power assisted rack and pinion steering gear assembly |
US6209183B1 (en) * | 1999-10-19 | 2001-04-03 | Trw Inc. | Bushing installation tool |
JP2001142371A (ja) | 1999-11-17 | 2001-05-25 | Canon Inc | 電子写真装置 |
JP2001231403A (ja) * | 2000-02-18 | 2001-08-28 | Kirin Brewery Co Ltd | 改変された外来染色体あるいはその断片を保持する非ヒト動物 |
US6457375B1 (en) * | 2000-07-25 | 2002-10-01 | Terry C. Buch | Rack and pinion assembly for use with steering mechanism of motor vehicles |
JP3794907B2 (ja) * | 2000-07-28 | 2006-07-12 | 株式会社ジェイテクト | ラックピニオン式ステアリング装置 |
US6427552B1 (en) * | 2000-10-20 | 2002-08-06 | Trw Inc. | Rack and pinion steering gear with spring and relief pocket |
ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
US7476536B2 (en) * | 2001-05-11 | 2009-01-13 | Kirin Pharma Kabushiki Kaisha | Artificial human chromosome containing human antibody a light chain gene |
US6681885B2 (en) * | 2001-09-19 | 2004-01-27 | Trw Inc. | Rack and pinion steering gear with powdered metal bushing |
US6467566B1 (en) * | 2001-09-24 | 2002-10-22 | Trw Inc. | Integral bushing assembly for a rack and pinion steering gear |
US7435871B2 (en) * | 2001-11-30 | 2008-10-14 | Amgen Fremont Inc. | Transgenic animals bearing human Igλ light chain genes |
-
2002
- 2002-05-10 US US10/477,471 patent/US7476536B2/en not_active Expired - Lifetime
- 2002-05-10 AU AU2002309063A patent/AU2002309063B8/en not_active Expired
- 2002-05-10 CA CA2446968A patent/CA2446968C/en not_active Expired - Lifetime
- 2002-05-10 DK DK02769569T patent/DK1391511T3/da active
- 2002-05-10 KR KR1020037014594A patent/KR100770065B1/ko active IP Right Grant
- 2002-05-10 DE DE60227067T patent/DE60227067D1/de not_active Expired - Lifetime
- 2002-05-10 EP EP02769569A patent/EP1391511B1/en not_active Expired - Lifetime
- 2002-05-10 KR KR1020057009130A patent/KR100583331B1/ko active IP Right Grant
- 2002-05-10 AT AT02769569T patent/ATE398172T1/de not_active IP Right Cessation
- 2002-05-10 EP EP08010546A patent/EP1970448A1/en not_active Withdrawn
- 2002-05-10 CN CN2005101137661A patent/CN1789416B/zh not_active Expired - Lifetime
- 2002-05-10 CN CNB028135202A patent/CN100448992C/zh not_active Expired - Lifetime
- 2002-05-10 CA CA2508763A patent/CA2508763C/en not_active Expired - Lifetime
- 2002-05-10 WO PCT/JP2002/004587 patent/WO2002092812A1/ja active IP Right Grant
- 2002-05-10 EP EP05012976A patent/EP1632571B1/en not_active Expired - Lifetime
- 2002-05-10 JP JP2002589679A patent/JP4115281B2/ja not_active Expired - Lifetime
-
2005
- 2005-05-16 JP JP2005142475A patent/JP4192162B2/ja not_active Expired - Lifetime
- 2005-06-03 AU AU2005202417A patent/AU2005202417B2/en not_active Expired
- 2005-06-14 US US11/151,227 patent/US7402729B2/en not_active Expired - Lifetime
-
2006
- 2006-09-08 HK HK06109996.9A patent/HK1089480A1/xx not_active IP Right Cessation
-
2008
- 2008-06-16 US US12/140,009 patent/US9499838B2/en active Active
-
2016
- 2016-10-19 US US15/298,037 patent/US10448622B2/en not_active Expired - Lifetime
-
2019
- 2019-09-12 US US16/568,616 patent/US20200236915A1/en not_active Abandoned
-
2021
- 2021-03-09 US US17/196,608 patent/US20210298277A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100770065B1 (ko) | 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는비인간 동물 | |
KR100855998B1 (ko) | 비동족형 스위치 영역에 의해 인간 항체의 특정 이소타입을 생산하는 트랜스제닉 동물 | |
JP2022066449A (ja) | ハイブリッド軽鎖マウス | |
US8110671B2 (en) | Isolated human chromosome 14 fragment encoding immunoglobulin genes | |
CA2428053C (en) | Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates | |
EP1106061A1 (en) | Method for modifying chromosomes | |
EP1707051B1 (en) | Human chromosome fragment, and vector containing it | |
WO2009111086A1 (en) | Transgenic non-human mammals with kappa light chain of xenogenous immunoglobulin | |
JP2001231403A (ja) | 改変された外来染色体あるいはその断片を保持する非ヒト動物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120327 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20130327 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160311 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170329 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180403 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190329 Year of fee payment: 14 |